Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer

Complete macroscopic surgical resection (CMR) requires extensive surgery and combined with chemotherapy confers best chance of survival in advanced ovarian cancer. During cytoreductive surgery 11% of women require a temporary diverting intestinal stoma. Unexpectedly, our results from a unique fully accounted for population demonstrate that survival was not improved when increasing the proportion of women in whom CMR was achieved and in a yet unidentified subgroup of women extensive surgery was detrimental. In these women surgical treatment should be omitted in favor of chemotherapy only. Acco

Trial Details

NCT ID
NCT06298877
Phase
NA
Sponsor
Sahar Salehi
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Frailty and Quality of Life evaluation
Locations (sample)
  • Stockholm, Solna, Sweden|59.32938,18.06871
  • Gothenburg, Sweden|57.70716,11.96679
  • Linköping, Sweden|58.41086,15.62157
  • Lund, Sweden|55.70584,13.19321

Key Eligibility Criteria

  • Women with epithelial ovarian cancer scheduled for cytoreductive surgery with curative intent
  • Age ≥18 years
  • Signed written informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →